好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effectiveness and Satisfaction with Deutetrabenazine in Huntington Disease When Initiated Using a 4-week Patient Titration Kit: Final Results of the START Study
Movement Disorders
P8 - Poster Session 8 (5:30 PM-6:30 PM)
3-008

To evaluate real-world effectiveness and patient and healthcare professional (HCP) satisfaction with deutetrabenazine, initiated using a 4-week patient titration kit.
Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-associated chorea. The kit was launched (July 2021) to assist patients in titrating to optimal deutetrabenazine dosages.

START was a 2-cohort (TD and HD) study evaluating real-world usage of deutetrabenazine when initiated using the kit. Final results from the HD cohort are presented here.
The HD cohort included 17 patients (mean age, 53.1 years; 53% male; 88% White; mean baseline Total Maximal Chorea [TMC] score, 12.8). 13/17 (76%) patients successfully completed the kit (completed within 5 weeks or reached optimal dose [≥24 mg/day] within 4 weeks); the mean (SE) adherence rate was 92% (6%). 8/16 (50%) patients achieved treatment success (“much”/“very much” improved) at week 12 per Clinical Global Impression of Change (GIC); 10/16 (63%) per Patient GIC. Mean TMC scores decreased by 4.4 (41%) from baseline to week 12. Among 12 (71%) patients responding to the custom patient satisfaction questionnaire, 92% found it easy to change dosages weekly and to understand when/which dosage to take, and 100% to use the kit overall; 83% found the kit helpful to remember taking medication. Among 7 (100%) HCPs responding to the custom HCP questionnaire, 100% found the kit helpful to ensure patient adherence to the titration schedule and 86% were satisfied with providing the kit to patients. Adverse events overall and those leading to study discontinuation were reported for 4/17 (24%) and 1/17 (6%) patient(s), respectively.
The 4-week patient titration kit enabled patients to titrate to optimal deutetrabenazine dosages with effectiveness similar to that of pivotal clinical trials and with high patient and HCP satisfaction.
Authors/Disclosures
Karen E. Anderson
PRESENTER 		Ms. Anderson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for teva. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AskBio. The institution of Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis. The institution of Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Biogen. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Ms. Anderson has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for neurocrine. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medscape. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for atheneum. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GLG. Ms. Anderson has received personal compensation in the range of $500-$4,999 for serving as a scientific advisor with CHDI.
Pooja Gandhi
PRESENTER 		Pooja Gandhi has received personal compensation for serving as an employee of Teva Pharmaceuticals. Pooja Gandhi has stock in Teva Pharmaceuticals.
Martijn Konings (Teva Pharmaceutical Inc.) Martijn Konings has received personal compensation for serving as an employee of Teva Pharmaceuticals. Martijn Konings has stock in Teva Pharmaceuticals.
Stacy Finkbeiner Stacy Finkbeiner has received personal compensation for serving as an employee of Teva Pharmaceuticals.
James Bennett No disclosure on file
Michael Soileau, MD, FAAN (Texas Movement Disorder Specialists, PLLC) The institution of Dr. Soileau has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. The institution of Dr. Soileau has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. The institution of Dr. Soileau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. Soileau has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Soileau has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Abbvie. Dr. Soileau has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. The institution of Dr. Soileau has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Soileau has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merz. The institution of Dr. Soileau has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Soileau has received research support from Abbvie. The institution of Dr. Soileau has received research support from Cerevel. The institution of Dr. Soileau has received research support from Praxis. The institution of Dr. Soileau has received research support from CND Life Sciences. The institution of Dr. Soileau has received research support from Teva. The institution of Dr. Soileau has received research support from Abbott. The institution of Dr. Soileau has received research support from Jazz Pharmaceuticals. The institution of Dr. Soileau has received research support from Scion. Dr. Soileau has received publishing royalties from a publication relating to health care. Dr. Soileau has a non-compensated relationship as a Past President with Texas Neurological Society that is relevant to AAN interests or activities.
Andrew Cutler Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for AbbVie. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Alkermes. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Axsome. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Boehringer Ingelheim. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Bristol Myers Squibb. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Delpor. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for 4M Therapeutics. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Intra-Cellular Therapies. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for J&J. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Jazz Pharma. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Lundbeck. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for MapLight Therapeutics. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Neumora. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Neurocrine. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Noven. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Otsuka. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Relmada. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Supernus. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Teva. Andrew Cutler has received personal compensation in the range of $0-$499 for serving as a Consultant for Tris Pharma. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for COMPASS Pathways. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Freedom Biosciences. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for AbbVie. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkermes. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Axsome. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Intra-Cellular Therapies. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for J&J. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Lundbeck. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Neurocrine. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Noven. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Otsuka. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Supernus. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Teva. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Tris Pharma. Andrew Cutler has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Vanda Pharmaceuticals. Andrew Cutler has stock in 4M Therapeutics. Andrew Cutler has stock in Relmada.